Ezetimibe, on the other hand, has been shown to partially protect against albuminuria and CKD progression in Col4a3−/− mice by reducing CD36-dependent fatty acid uptake and triglyceride content [26]. The gene discussed is CD36; the disease is chronic kidney disease.